Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
Not Confirmed
Not Confirmed
17-21 January, 2026
Not Confirmed
Not Confirmed
21-22 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
Industry Trade Show
Not Confirmed
17-21 January, 2026
Industry Trade Show
Not Confirmed
21-22 January, 2026
Digital content
NEWS #PharmaBuzz
09 Dec 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/cytovia-therapeutics-presents-new-data-on-cd38-targeted-flex-nk-bispecific-antibody-at-2022-american-society-of-hematology-annual-meeting-301698987.html
09 Dec 2022
// BIONJ
07 Nov 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/cytovia-therapeutics-presents-new-data-on-talen-gene-edited-ink-cells-and-gpc3-targeted-flex-nk-bispecific-antibodies-at-2022-sitc-annual-meeting-301669887.html
27 Oct 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/cytovia-therapeutics-to-present-new-data-on-cd38-flex-nk-cell-engager-bispecific-antibodies-for-multiple-myeloma-at-2022-ash-annual-meeting-301661737.html
12 Sep 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/cytovia-therapeutics-presents-new-preclinical-data-for-its-gpc3-flex-nk-cell-engager-antibody-in-combination-with-natural-killer-cells-at-esmo-2022-in-paris-301621698.html
10 Jun 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/cytovia-therapeutics-presents-antitumor-activity-of-its-cd38-targeting-flex-nk-cell-engager-antibody-at-eha-2022-congress-301565565.html
Drugs in Development
Details:
Under the partnership, Cytovia will be responsible for the differentiation and expansion of the gene-edited iPSC-derived NK Cells and will conduct the pre-clinical evaluation, clinical development, and commercialization of the selected therapeutic candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Recipient: Cellectis
Deal Size: $825.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration January 20, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Cellectis
Deal Size : $825.0 million
Deal Type : Collaboration
Details : Under the partnership, Cytovia will be responsible for the differentiation and expansion of the gene-edited iPSC-derived NK Cells and will conduct the pre-clinical evaluation, clinical development, and commercialization of the selected therapeutic candid...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $20.0 million
January 20, 2023
Details:
CYT-338 is a tetravalent IgG1-like multifunctional NK cell engager antibody with a novel FLEX-linker that simultaneously binds CD38-expressing cells and NK cells via the activation receptor NKp46.
Lead Product(s): CYT-338
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 27, 2022
Lead Product(s) : CYT-338
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CYT-338 is a tetravalent IgG1-like multifunctional NK cell engager antibody with a novel FLEX-linker that simultaneously binds CD38-expressing cells and NK cells via the activation receptor NKp46.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 27, 2022
Details:
CYT-338 is a tetravalent IgG1-like multifunctional NK cell engager antibody with a novel FLEX-linker that simultaneously binds CD38-expressing cells and NK cells via the activating receptor NKp46.
Lead Product(s): CYT-338
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 10, 2022
Lead Product(s) : CYT-338
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CYT-338 is a tetravalent IgG1-like multifunctional NK cell engager antibody with a novel FLEX-linker that simultaneously binds CD38-expressing cells and NK cells via the activating receptor NKp46.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 10, 2022
Details:
Cellectis has granted Cytovia a worldwide license under the patent rights over which Cellectis has control in this field, including in China, in order for Cytovia to modify NK cells to address multiple gene-targets for therapeutic use in several cancer indications.
Lead Product(s): CYT-303,Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Recipient: Cellectis
Deal Size: $825.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration April 27, 2022
Lead Product(s) : CYT-303,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Cellectis
Deal Size : $825.0 million
Deal Type : Collaboration
Details : Cellectis has granted Cytovia a worldwide license under the patent rights over which Cellectis has control in this field, including in China, in order for Cytovia to modify NK cells to address multiple gene-targets for therapeutic use in several cancer i...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : $20.0 million
April 27, 2022
Details:
In addition, CYT-503, a GPC3-targeting CAR-iNK cell therapeutic, is designed to improve specificity for tumor targeting. Cytovia expects to file INDs for CYT-303 and CYT-100, followed by INDs for CYT-150 and CYT-503.
Lead Product(s): CYT-303,Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Sponsor: Isleworth Healthcare Acquisition Corp.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger April 26, 2022
Lead Product(s) : CYT-303,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Isleworth Healthcare Acquisition Corp.
Deal Size : Undisclosed
Deal Type : Merger
Details : In addition, CYT-503, a GPC3-targeting CAR-iNK cell therapeutic, is designed to improve specificity for tumor targeting. Cytovia expects to file INDs for CYT-303 and CYT-100, followed by INDs for CYT-150 and CYT-503.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
April 26, 2022
Details:
First in vivo data demonstrated anti-tumor activity of Glypican-3 (GPC3) Flex-NKâ„¢ cell engager CYT-303 in combination with iNK cells in an animal model of Hepatocellular carcinoma (HCC).
Lead Product(s): CYT-303,iNK Cell
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 08, 2022
Lead Product(s) : CYT-303,iNK Cell
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First in vivo data demonstrated anti-tumor activity of Glypican-3 (GPC3) Flex-NKâ„¢ cell engager CYT-303 in combination with iNK cells in an animal model of Hepatocellular carcinoma (HCC).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 08, 2022
Details:
CYT 303 is a FLEX-NK® tetravalent bispecific trifunctional antibody targeting GPC3, a glycoprotein highly expressed on solid tumors, including Hepatocellular carcinoma, but not on adult healthy cells, is being developed to treat solid tumors expressing GPC3, including HCC.
Lead Product(s): CYT-303
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 16, 2022
Lead Product(s) : CYT-303
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CYT 303 is a FLEX-NK® tetravalent bispecific trifunctional antibody targeting GPC3, a glycoprotein highly expressed on solid tumors, including Hepatocellular carcinoma, but not on adult healthy cells, is being developed to treat solid tumors expressing ...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 16, 2022
Details:
Cellectis is granting Cytovia a worldwide license under the patent rights over which Cellectis has the control in this field, including in China, enabling Cytovia to modify NK cells to address multiple gene-targets for therapeutic use in several cancer indications.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Recipient: Cellectis
Deal Size: $825.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration November 18, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Cellectis
Deal Size : $825.0 million
Deal Type : Collaboration
Details : Cellectis is granting Cytovia a worldwide license under the patent rights over which Cellectis has the control in this field, including in China, enabling Cytovia to modify NK cells to address multiple gene-targets for therapeutic use in several cancer i...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 18, 2021
Details:
TF Capital, a leading China-based biotech institutional investor and Cytovia have formed CytoLynx Therapeutics, and invests to finance the IND enabling and initial clinical development of the pipeline programs including CYT-303.
Lead Product(s): CYT-303
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Sponsor: TF Capital
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 13, 2021
Lead Product(s) : CYT-303
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : TF Capital
Deal Size : $45.0 million
Deal Type : Financing
Details : TF Capital, a leading China-based biotech institutional investor and Cytovia have formed CytoLynx Therapeutics, and invests to finance the IND enabling and initial clinical development of the pipeline programs including CYT-303.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
September 13, 2021
Details:
CytoLynx obtained a technology license from Cytovia based on its core technologies to allow in-China development of additional NK therapeutics for global commercialization including CYT-100.
Lead Product(s): CYT-100
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Sponsor: CytoLynx
Deal Size: Undisclosed Upfront Cash: $400.0 million
Deal Type: Collaboration September 13, 2021
Lead Product(s) : CYT-100
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : CytoLynx
Deal Size : Undisclosed
Deal Type : Collaboration
Details : CytoLynx obtained a technology license from Cytovia based on its core technologies to allow in-China development of additional NK therapeutics for global commercialization including CYT-100.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : $400.0 million
September 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
